Effect of vehicles and enhancers on the topical delivery of cyclosporin A

Liu, Hongzhuo; Li, Sanming; Wang, Yongjun; Yao, Huimin; Zhang, Yan

doi:10.1016/j.ijpharm.2005.12.029

Cited by 65 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rat skin, pretreated with SLS (0.5% w/w) was found to reduce the lag time for cyclosporin A penetration into deeper skin layers, and enhance the amount of cyclosporin A retained in the skin, compared to control [148]. Furthermore, the surfactant was shown to enhance the amount of drug permeated across rat skin 2-fold after 12 hours.…”

Section: Surfactantsmentioning

confidence: 97%

“…DMSO has a long history of being used as a permeation enhancer, and several reviews have highlighted its ability to enhance the penetration of both hydrophilic and hydrophobic drugs [20,145,146]. Recent studies have shown significant improvement in skin penetration in vitro of azathioprine [147], cyclosporin A [148] and prazosin [149]. However, Jantharaprapap and Stagni [150] reported no improvement in meloxicam penetration across excised human skin, using vehicles containing up to 10% DMSO.…”

Section: Dimethylsuphoxidementioning

confidence: 99%

“…NMP and 2P enhanced drug penetration rates 1.5-and 3.0-fold, respectively, compared to control. Liu et al [148] reported enhanced topical deposition of cyclosporin A, into excised rat skin pre-treated with NMP, compared to control. However, the authors reported no significant increase in transdermal delivery of the drug.…”

Section: Pyrrolidonesmentioning

confidence: 99%

“…Terpenes have been used in vitro in enhance skin penetration of caffeine [181], cyclosporin A [148], diclofenac [182], hydrocortisone [181], anipyrine [183], indomethacin [183], 5-fluorouracil [184], meloxicam [166], midazolam [185], and sumatriptan [186]. Amnuaikit et al [187] prepared polymeric films containing propranolol, and the terpene, cineole.…”

Section: Terpenesmentioning

confidence: 99%

See 3 more Smart Citations

Innovative Strategies for Enhancing Topical and Transdermal Drug Delivery

Morrow¹,

McCarron²,

Woolfson³

et al. 2007

TODDJ

View full text Add to dashboard Cite

Abstact: Historically, the skin was thought to be a simple homogenous barrier. However, it is now known to be a highly specialised organ, and plays a key role in homeostasis. The protective properties of the skin are provided by the outermost layer, the epidermis, which safeguards against chemical, microbial, and physical attack. The exceptional barrier properties of the skin result in it being a challenging route for the delivery of therapeutic agents. This article reviews strategies developed to enhance the skin penetration of drugs, ranging from conventional approaches, for example the use of chemical penetration enhancers to those in early-stage development, such as microscissioning.

show abstract

Section: Surfactantsmentioning

confidence: 97%

Section: Dimethylsuphoxidementioning

confidence: 99%

Section: Pyrrolidonesmentioning

confidence: 99%

Section: Terpenesmentioning

confidence: 99%

See 2 more Smart Citations

Innovative Strategies for Enhancing Topical and Transdermal Drug Delivery

Morrow¹,

McCarron²,

Woolfson³

et al. 2007

TODDJ

View full text Add to dashboard Cite

show abstract

“…nach intradermaler Applikation eine deutliche Penetrationsverbesserung bzw. Wirkeffekte nachweisen konnten [6,20]. Als Begründung für die topische Effektivität wurde ausgeführt, dass sich nur die behandelten Lä-sionen besserten, unbehandelte Plaques am selben Patienten aber unverändert blieben.…”

Section: Ciclosporinunclassified

Calcineurininhibitoren zur topischen Therapie der Psoriasis

Wohlrab

2006

Hautarzt

View full text Add to dashboard Cite

There are numerous possibilities for specific antiinflammatory therapy of psoriasis. One option is the use of calcineurin inhibitors. To date, only systemic administration of cyclosporine A is approved for this indication. Nonetheless cyclosporine A, tacrolimus and pimecrolimus can all be classed as effective anti-inflammatory agents for the therapy of psoriasis. Unfortunately, the vehicles currently available do not insure adequate topical delivery of these substances. Clinical efficacy of the preparations can be proven only when additional penetration-promoting measures are used or penetration-facilitating conditions exist. The entire group can be expected to play a greater role in the topical therapy of psoriasis if advances in vehicles and delivery systems are made.

show abstract

Efficacy of Novel Topical Liposomal Formulation of Cyclosporine in Mild to Moderate Stable Plaque Psoriasis

et al. 2016

View full text Add to dashboard Cite

IMPORTANCE Attempts to use topical cyclosporine in treatment of psoriasis have failed because of unfavorable physicochemical properties and inappropriate formulation design of the conventional dosage forms. OBJECTIVE To evaluate the efficacy of topical cyclosporine using liposomal nanocarriers (lipogel) in limited chronic plaque psoriasis. DESIGN, SETTING, AND, PARTICIPANTS A single-center randomized clinical trial was conducted using a 3-arm parallel group, double-blind, vehicle and active comparator design and included 38 patients with chronic plaque psoriasis measuring less than or equal to 100 cm 2 performed in a tertiary care hospital. INTERVENTIONS In the first arm, a total of 24 patients were randomized to receive either cyclosporine lipogel, 2.0% weight by weight (w/w), or placebo lipogel. In the second arm, 7 patients were randomized to receive cyclosporine lipogel, 2.0%, or conventional cyclosporine cream, 2.0% w/w. The third arm comprised 7 patients randomized with cyclosporine lipogel, 2.0% or standard clobetasol propionate cream, 0.05% w/w. Patients were examined twice weekly for 14 weeks, or until total lesional clearance was observed, whichever was earlier. MAIN OUTCOMES AND MEASURES The primary outcome measure was the dermatological sum score (DSS) assessing erythema, scaling, and plaque elevation on a 4-point scale (0, absent; 1, minimal; 2, moderate; 3, severe). RESULTS In 38 patients (23 men and 15 women with a mean [SD] age range from 35 [8] to 40 [13] years), a 19% decrease in DSS score from a mean (SD) of 8.45 (0.67) to 6.82 (0.77) compared with baseline was observed after 2 weeks of treatment with cyclosporine lipogel, 2.0% w/w (P < .001; 95% CI, 13.77-24.51) in 59% of psoriasis lesional sites. At the end of the eighth week, a significant reduction (approximately 83%) in DSS was seen in all sites treated with cyclosporine lipogel, (P < .001; 95% CI, 77.48-88.22). At the end of the study period, complete clearance (ie, DSS = 0) was observed in 16 (41%) psoriasis lesional sites treated with cyclosporine lipogel, 85.7% of sites treated with clobetasol propionate cream, and none of the sites treated with conventional cyclosporine cream or placebo gel. CONCLUSIONS AND RELEVANCE Topical liposomal formulation of cyclosporine, 2.0% w/w, is effective in treatment of limited chronic plaque psoriasis with a satisfactory safety profile. Future clinical trials should assess liposomal cyclosporine in larger study populations.

show abstract

Effect of vehicles and enhancers on the topical delivery of cyclosporin A

Cited by 65 publications

References 31 publications

Innovative Strategies for Enhancing Topical and Transdermal Drug Delivery

Innovative Strategies for Enhancing Topical and Transdermal Drug Delivery

Calcineurininhibitoren zur topischen Therapie der Psoriasis

Efficacy of Novel Topical Liposomal Formulation of Cyclosporine in Mild to Moderate Stable Plaque Psoriasis

Contact Info

Product

Resources

About